Braveheart Bio executive buys shares, receives options
Braveheart Bio, Inc. Chief Development Officer Michele A. Anderson reported two equity transactions.
Rhea-AI Filing Summary
Braveheart Bio, Inc. Chief Development Officer Michele A. Anderson reported two equity transactions. On August 7, 2026, she purchased 1,111 shares of Common Stock at $18.00 per share, bringing her direct holdings to 332,161 Common shares. On August 5, 2026, she received a grant of options for 300,000 shares of Common Stock at an exercise price of $18.00, expiring on August 4, 2036. According to the grant terms, 1/48th of the option shares vest in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to her continuous service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 1,111 shares
Net Buy
2 txns
Insider
Anderson Michele A.
Role
Chief Development Officer
Bought
1,111 shs ($20K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,111 | $18.00 | $20K |
| Grant/Award | Stock Option (Right to Buy) F1 | 300,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 300,000 contracts (Direct);
Common Stock — 332,161 shares (Direct)
Footnotes (1)
- F1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Common shares purchased: 1,111 shares
Purchase price: $18.00 per share
Common shares held after purchase: 332,161 shares
+4 more
7 metrics
Common shares purchased
1,111 shares
Open-market or private purchase on August 7, 2026 at $18.00 per share
Purchase price
$18.00 per share
Price paid for 1,111 Common shares on August 7, 2026
Common shares held after purchase
332,161 shares
Total direct Common Stock ownership following August 7, 2026 transaction
Option shares granted
300,000 shares
Stock Option (Right to Buy) grant on August 5, 2026
Option exercise price
$18.00 per share
Exercise price for 300,000-share stock option grant
Option expiration date
August 4, 2036
Expiration of Stock Option (Right to Buy) granted August 5, 2026
Vesting rate
1/48th monthly
Option vests in substantially equal monthly installments from July 23, 2026
Key Terms
Stock Option (Right to Buy), exercise price, vesting, continuous service
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with 300,000 underlying shares"
exercise price financial
"conversion_or_exercise_price of 18.0000 per share for the option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/48th of the shares subject to such option vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Common Stock did Braveheart Bio (BRVE) executive Michele Anderson buy?
Michele A. Anderson purchased 1,111 shares of Braveheart Bio Common Stock at $18.00 per share on August 7, 2026, increasing her direct ownership to 332,161 Common shares after the transaction.
What stock option grant did Michele Anderson receive at Braveheart Bio (BRVE)?
On August 5, 2026, Michele A. Anderson received a stock option grant for 300,000 shares of Braveheart Bio Common Stock with an $18.00 exercise price and an expiration date of August 4, 2036.
How do Michele Anderson’s Braveheart Bio (BRVE) options vest?
The option for 300,000 shares vests so that 1/48th of the shares vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, conditioned on her continuous service with Braveheart Bio.
What is Michele Anderson’s total direct Common Stock holding in BRVE after these transactions?
Following the 1,111-share purchase at $18.00, Michele A. Anderson directly holds 332,161 shares of Braveheart Bio Common Stock. This figure reflects the reported total direct ownership after the August 7, 2026 transaction.
Were Michele Anderson’s Braveheart Bio (BRVE) trades under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as a plan trade, and no footnote indicates a trading plan. The 1,111-share purchase is described simply as an open-market or private transaction purchase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
